A Phase 1 interventional study of Influenza Virus Quadrivalent Inactivated Vaccine and Sodium Chloride, 0.9% in Influenza, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) — 11 open to participants now, 12 under way, none of them phase 3. Influenza, Human · National Institute of Allergy and Infectious Diseases (NIAID).
Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), this one is the 107th largest by enrollment of the 166 interventional ones that give a count, is one of 5 that started in 2023, is one of 77 in phase 1, and was the 175th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →11 of the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) are open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–59 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–55 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3–17
By country, each count listing its studies:
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
186 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 96 · Phase 2 67 · Phase 3 5 · Phase 4 11
First in 2000; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 83 across the 166 interventional studies, 190 across the 20 observational. Of the 165 that completed or were terminated, 53 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,449 studies on the registry; 181 are open to participants now.
Of its 406 completed or terminated interventional studies of FDA-regulated products, 303 (75%) have results posted.
9 of the studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07110532National Institute of Allergy and Infectious Diseases (NIAID)pH1N1 Blinded Challenge Study | 2027-03-29 |
| NCT07703514National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates | 2027-04-12 |
| NCT07169318National Institute of Allergy and Infectious Diseases (NIAID)First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics | 2027-05-01 |
| NCT06863142National Institute of Allergy and Infectious Diseases (NIAID)Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults | 2027-05-10 |
| NCT02511002National Institute of Allergy and Infectious Diseases (NIAID)Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge | 2027-05-12 |
Add all 9 to your calendar (.ics) → With an account.
Among the 186 studies in Influenza, Human by National Institute of Allergy and Infectious Diseases (NIAID), from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, single-site, open-label, comparator-controlled dose escalating study of an intramuscularly (IM) administered mRNA-LNP vaccine encoding for (Vaccine Research Center) VRC H1ssF 3928 of up to 50 healthy adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of one dose of H1ssF 3928 mRNA Vaccine. Eligible participants will be sequentially enrolled into dosing groups (10 mcg, 25 mcg, and 50 mcg, selected optimal dose) to receive the H1ssF 3928 mRNA Vaccine at the specified dose. A separate group of 10 participants will receive licensed quadrivalent influenza vaccine (IIV4). Subjects receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving H1ssF 3928 mRNA Vaccine. Dosing of H1ssF 3928 mRNA Vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified. Up to ten subjects will be enrolled per dosing cohort. Reactogenicity and adverse event (AE) information through Day 7 and clinical laboratory results through Day 8 from the first three dosing groups will guide the selection of an optimal dose group to include 10 subjects who will receive the optimal dose of mRNA-LNP. The primary objective of this study is to assess the safety of a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults, 18-49 yrs, at doses of 10 mcg, 25 mcg, and 50 mcg.
This is a Phase 1, single-site, open-label, comparator-controlled dose escalating study of an intramuscularly (IM) administered mRNA-LNP vaccine encoding for (Vaccine Research Center) VRC H1ssF 3928 of up to 50 healthy adult volunteers aged 18 to 49 years, inclusive. This study is designed to assess the safety and immunogenicity of one dose of H1ssF 3928 mRNA Vaccine. Eligible participants will be sequentially enrolled into dosing groups (10 mcg, 25 mcg, and 50 mcg, selected optimal dose) to receive the H1ssF 3928 mRNA Vaccine at the specified dose. A separate group of 10 participants will receive licensed quadrivalent influenza vaccine (IIV4). Subjects receiving IIV4 will be followed for safety but only their immune responses will be compared to those of participants receiving H1ssF 3928 mRNA Vaccine. Dosing of H1ssF 3928 mRNA Vaccine will commence at the lowest dose (10 mcg) and only escalate to the next highest dose if safety concerns are not identified. For each VRC H1ssF 3928 mRNA-LNP (Lipid Nanoparticle) dosing group, the first two subjects enrolled will be considered the sentinel subgroup. After the two subjects in the Low Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a review of the reactogenicity and safety data collected through Day 3 for both subjects. Approval by the reviewing group will allow for continued enrollment of the remaining Low Dose Group subjects to complete enrollment of 10 participants. After Low Dose Group enrollment is completed, enrollment will be stopped pending an Safety Review Committee (SRC) review of the reactogenicity and adverse event (AE) information through Day 7 and clinical laboratory results through Day 8 for all Low Dose Group subjects. Approval will allow dose escalation and initiation of enrollment of the Medium Dose Group sentinel subgroup. After the two subjects in the Medium Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a safety review of the sentinel subgroup as specified for the Low Dose Group. Approval will allow for continued enrollment of Medium Dose Group subjects to complete enrollment of 10 participants. After the Medium Dose Group enrollment is completed, enrollment will be stopped pending an SRC review of the reactogenicity and adverse event information through Day 7 and clinical laboratory results through Day 8 for all Medium Dose Group subjects. Approval will allow dose escalation and initiation of enrollment of the High Dose Group sentinel subgroup. After the two subjects in the High Dose sentinel subgroup are enrolled and given their vaccination, enrollment will then be stopped pending a safety review of the sentinel subgroup as specified for the Low and Medium Dose Groups. Approval will allow for continued enrollment of High Dose Group subjects to complete enrollment of 10 participants. After the High Dose Group enrollment is completed, enrollment will be stopped pending an SRC review of the reactogenicity and adverse event information through Day 7 visit and clinical laboratory results through Day 8 for all High Dose Group subjects. Reactogenicity and AE information through Day 7 and clinical laboratory results through Day 8 from the first three dosing groups will guide the selection of an optimal dose group to include an additional 10 subjects who will receive the optimal dose of mRNA-LNP. The primary objective of this study is to assess the safety of a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults, 18-49 yrs, at doses of 10 mcg, 25 mcg, and 50 mcg. The secondary objective of this study is to assess serum antibody responses to a single dose of VRC H1ssF 3928 mRNA-LNP vaccine administered IM in healthy adults at doses of 10 mcg, 25 mcg, and 50 mcg in comparison to a standard dose of IIV4.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Are in good health* and do not have medical, psychiatric, chronic or intermittent health conditions including those listed in Exclusion Criteria (Section 1).
*As determined by medical history, medication use, and physical examination to evaluate ongoing chronic medical or psychiatric diagnoses or conditions, defined as those that have been present for at least 90 days, which would not affect the assessment of the safety of subjects or the immunogenicity of study vaccinations. These medical diagnoses or conditions should be stable for the last 60 days (no hospitalizations, emergency room [ER] or urgent care for condition [excluding musculoskeletal conditions], or invasive medical procedure and no adverse symptoms that need medical intervention such as medication change/supplemental oxygen). This includes no change in chronic prescription medication, dose or in the 60 days prior to enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, as long as in the same class of medication, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site PI or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening or treatment of continued symptoms of medical diagnosis or condition. Note: Low dose topical, as outlined in the Subject Exclusion Criteria (see Section 1) as well as herbals, vitamins and supplements are permitted.
Does not have an ongoing symptomatic condition* for which subject has had or has ongoing medical investigations but has not yet received a diagnosis or treatment plan.
*e.g., ongoing fatigue without a diagnosis for symptom.
Women of * must agree to use or have practiced true abstinence** or use at least 1 acceptable primary form of .***
*Not of child bearing potential - females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, salpingectomy, or Essure placement with history of documented radiological confirmation test at least 90 days after the procedure).
**True abstinence is 100% of time no sexual intercourse (male's penis enters the female's vagina). (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception).
Male participants receiving VRC H1ssF_3928 mRNA-LNP must agree to refrain from donating sperm and to use contraception until Day 60 after vaccination.*
Exclusion Criteria:
Have an acute illness* or fever (body temperature > / = 38.0 degrees Celsius/100.4 degrees Fahrenheit), as determined by the site Principal Investigator (PI) or appropriate sub-investigator, within 72 hours prior to study vaccination.
*An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.
Have any medical disease or condition that, in the opinion of the site PI or appropriate sub-investigator, is a to study participation.*
* Including acute, subacute, intermittent or chronic medical disease or condition that would place the subject at an unacceptable risk of injury, render the subject unable to meet the requirements of the protocol, or may interfere with the evaluation of responses or the subject's successful completion of this trial.
Has a screening laboratory* > Grade 1.
*White blood cell count, , absolute lymphocyte count, , count, (PT), activated partial thromboplastin time (APTT), fibrinogen, creatinine, (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total , lipase.
Have any diagnosis, current or past, of schizophrenia, bipolar disease or other psychiatric diagnosis that may interfere* with subject compliance or safety evaluations.
*As determined by the site PI or appropriate sub-investigator.
Have taken high-dose inhaled or nebulized corticosteroids* within 30 days prior to study vaccination.
*High-dose defined as per age as using inhaled high-dose per reference chart in the National Heart, Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma (EPR-3) or other lists published in UPTODATE
Received an experimental agent *within 60 days prior to the study vaccination or expect to receive another experimental agent during the trial-reporting period.**
*Including vaccine, drug, biologic, device, blood product, or medication.
**Other than from participation in this trial
Are participating or plan to participate in another clinical trial with an interventional agent* that will be received during the trial-reporting period.*
Has had significant exposure to someone with laboratory-confirmed severe acute respiratory syndrome (SARS-CoV-2) infection or influenza in the 14 days prior to screening or during the period between screening and enrollment visit.*
*Defined by the Centers for Disease Control and Prevention (CDC) as a close contact with someone who has COVID-19.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 10 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 10 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)
10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 25 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 25 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. N = 10
Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)
Experimental: Arm 3, High Dose 10 healthy adult volunteer subjects from 18-49 years of age are split into two subgroups. The sentinel subgroup includes 2 vaccine recipients who will receive 50 mcg of the H1ssF\_3928 mRNA Vaccine, administered intramuscularly once. The sentinel subgroup is observed for 8 days to monitor any early vaccine related adverse events. After the observation period, the remaining participants will receive the same dosage, 50 mcg of the H1ssF 3928 mRNA vaccine administered intramuscularly once. The High Dose was selected as the optimal dose as it was the highest dose with no identified safety concerns by the Safety Review Committee (SRC). An additional 10 (optimal dose) participants were therefore enrolled into the High Dose group. Total N = 20
Other: Sodium Chloride, 0.9% · Biological: VRC-FLUNPF099-00-VP (H1ssF_3928)
10 healthy adult volunteer subjects from 18-49 years of age will receive licensed Quadrivalent Influenza Vaccine (IIV4), administered intramuscularly once. Subjects receiving IIV4 will be followed for safety, but only their immune responses will be compared to those of participants receiving H1ssF\_3928 mRNA Vaccine. N=10
Biological: Influenza Virus Quadrivalent Inactivated Vaccine
A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
0.9% Sodium Chloride Injection
The vaccine consists of modified nucleoside messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNP), comprised of four lipid components: (ALC-307 (ionizable lipid), DSPC, cholesterol, and ALC-0159 \[PEG lipid\]).
Number and Percentage of Participants Experiencing Solicited Local and Systemic Reactogenicity Adverse Events (AEs)
Number and percentage of participants in each dose group experiencing solicited local and systemic reactogenicity adverse events, of all severity grades and by grade
Time frame: Day of vaccination through 13 days post-vaccination
Number and Percentage of Participants Experiencing Any Unsolicited AEs
Number and percentage of participants in each dose group experiencing unsolicited adverse events (AEs), of all severity grades and by grade
Time frame: Day of vaccination through 28 days post-vaccination
Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs)
Number and percentage of participants in each dose group experiencing NOCMCs
Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Adverse Events of Special Interest (AESIs) Corresponding to Grade 2 or Greater Decrease in Lymphocyte or Neutrophil Count
Number and percentage of participants in each dose group experiencing AESIs corresponding to Grade 2 or greater decrease in lymphocyte or neutrophil count
Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs)
Number and percentage of participants in each dose group experiencing ILIs
Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs)
Number and percentage of participants in each dose group experiencing SAEs
Time frame: Day of vaccination through end of study participation (approximately 365 days post-vaccination)
Number and Percentage of Participants Experiencing AESIs Corresponding to Myocarditis, Pericarditis, or Myopericarditis
Number and percentage of participants in each dose group experiencing AESIs corresponding to myocarditis, pericarditis, or myopericarditis
Time frame: Day of vaccination through 56 days post-vaccination
Number and Percentage of Participants Experiencing Clinical Laboratory AEs
Number and percentage of participants in each dose group experiencing clinical laboratory AEs
Time frame: Day of vaccination through 56 days post-vaccination
Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group. Rows are "VRC H1ssF\_3928 mRNA-LNP" and "VRC H1ssF\_3928 mRNA-LNP + Receipt of Prior Season's Influenza Vaccine"
Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Reporter Microneutralization Assay
Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
Time frame: Days 8, 15, 29, and 57
Geometric Mean Titers (GMT) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57
Geometric Mean Fold Rise (GMFR) of Homologous H1-specific Neutralizing Antibodies in a Viral Microneutralization Assay
Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
Time frame: Days 8, 15, 29, and 57
Geometric Mean Titers (GMT) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)
The geometric mean of titers is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
Time frame: Days 1 (day of vaccination), 8, 15, 29, and 57
Geometric Mean Fold Rise (GMFR) of Anti-stalk Serum Antibodies, Measured by Enzyme Linked Immunosorbent Assay (ELISA)
Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
Time frame: Days 8, 15, 29, and 57
| Milestone | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 |
|---|---|---|---|---|
| Started | 10 | 10 | 20 | 10 |
| Completed | 10 | 9 | 20 | 10 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
Number and percentage of participants in each dose group experiencing solicited local and systemic reactogenicity adverse events, of all severity grades and by grade
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Any Local Solicited Event — None | 0 | 0 | 1 | 1 | 4 |
| Any Local Solicited Event — Mild | 6 | 6 | 8 | 20 | 6 |
| Any Local Solicited Event — Moderate | 4 | 4 | 11 | 19 | 0 |
| Any Local Solicited Event — Severe | 0 | 0 | 0 | 0 | 0 |
| Any Systemic Solicited Event — None | 2 | 1 | 8 | 11 | 5 |
| Any Systemic Solicited Event — Mild | 7 | 7 | 8 | 22 | 4 |
| Any Systemic Solicited Event — Moderate | 1 | 1 | 4 | 6 | 1 |
| Any Systemic Solicited Event — Severe | 0 | 1 | 0 | 1 | 0 |
| Any Solicited Event — None | 0 | 0 | 0 | 0 | 3 |
| Any Solicited Event — Mild | 6 | 5 | 7 | 18 | 6 |
| Any Solicited Event — Moderate | 4 | 4 | 13 | 21 | 1 |
| Any Solicited Event — Severe | 0 | 1 | 0 | 1 | 0 |
Number and percentage of participants in each dose group experiencing unsolicited adverse events (AEs), of all severity grades and by grade
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Any Severity | 2 | 4 | 9 | 15 | 2 |
| Mild | 1 | 2 | 8 | 11 | 1 |
| Moderate | 1 | 0 | 0 | 1 | 1 |
| Severe | 0 | 2 | 1 | 3 | 0 |
Number and percentage of participants in each dose group experiencing NOCMCs
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Number and Percentage of Participants Experiencing Any New-onset Chronic Medical Conditions (NOCMCs) | 1 | 0 | 0 | 1 | 4 |
Number and percentage of participants in each dose group experiencing AESIs corresponding to Grade 2 or greater decrease in lymphocyte or neutrophil count
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| = Grade 2 decrease in lymphocyte count | 0 | 0 | 0 | 0 | 0 |
| = Grade 2 decrease in neutrophil count | 0 | 0 | 0 | 0 | 0 |
Number and percentage of participants in each dose group experiencing ILIs
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Number and Percentage of Participants Experiencing Any Influenza-like Illnesses (ILIs) | 1 | 3 | 1 | 5 | 0 |
Number and percentage of participants in each dose group experiencing SAEs
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Number and Percentage of Participants Experiencing Any Serious Adverse Events (SAEs) | 0 | 0 | 0 | 0 | 0 |
Number and percentage of participants in each dose group experiencing AESIs corresponding to myocarditis, pericarditis, or myopericarditis
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Myocarditis | 0 | 0 | 0 | 0 | 0 |
| Pericarditis | 0 | 0 | 0 | 0 | 0 |
| Myopericarditis | 0 | 0 | 0 | 0 | 0 |
Number and percentage of participants in each dose group experiencing clinical laboratory AEs
| Participants | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Any Non-IIV4 Dose | Arm 4, IIV4 |
|---|---|---|---|---|---|
| Number and Percentage of Participants Experiencing Clinical Laboratory AEs | 5 | 5 | 12 | 22 | 2 |
Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group. Rows are "VRC H1ssF\_3928 mRNA-LNP" and "VRC H1ssF\_3928 mRNA-LNP + Receipt of Prior Season's Influenza Vaccine"
| Titer | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Baseline - Dose Group | 87.6 (48.6 to 155.5) | 78.2 (40.4 to 150.8) | 151.3 (110.8 to 206.9) | 105.2 (62.8 to 172.8) |
| Day 8 - Dose Group | 99.6 (55.6 to 174.7) | 124.2 (67.3 to 219.9) | 199.9 (153.8 to 263.5) | 111.3 (70.1 to 175.5) |
| Day 15 - Dose Group | 123.0 (73.8 to 200.0) | 144.9 (84.6 to 252.3) | 236.4 (182.0 to 307.7) | 106.0 (64.5 to 172.4) |
| Day 29 - Dose Group | 125.0 (76.6 to 197.6) | 140.1 (87.3 to 219.0) | 217.4 (168.0 to 281.6) | 114.1 (71.1 to 178.3) |
| Day 57 - Dose Group | 113.9 (68.7 to 181.6) | 88.2 (49.7 to 144.0) | 196.7 (154.1 to 254.8) | 122.4 (75.4 to 199.9) |
| Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine | 76.2 (42.0 to 136.7) | 73.3 (35.3 to 150.4) | 154.4 (109.5 to 220.5) | 108.8 (58.0 to 194.7) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 87.6 (47.6 to 153.3) | 119.1 (60.2 to 219.1) | 200.3 (150.4 to 269.6) | 114.1 (66.8 to 197.9) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 109.8 (65.5 to 176.1) | 137.3 (75.8 to 253.9) | 239.0 (179.1 to 321.7) | 111.2 (61.4 to 200.2) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 112.9 (68.9 to 177.8) | 130.3 (79.3 to 213.9) | 217.1 (164.1 to 289.8) | 116.7 (66.5 to 197.9) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 102.0 (61.7 to 161.1) | 83.6 (45.5 to 142.5) | 196.1 (150.1 to 261.2) | 130.0 (71.6 to 232.7) |
| Baseline - Dose Group + No Receipt of Prior Season's Influenza Vaccine | 305.9 (NA to NA) | 140 (NA to NA) | 135 (81.9 to 325.5) | 91.9 (59.1 to 143) |
| Day 8 - Dose Group + No Receipt of Prior Season's Influenza Vaccine | 315 (NA to NA) | 181.1 (NA to NA) | 197.7 (126.7 to 399.6) | 100.7 (66.9 to 151.5) |
| Day 15 - Dose Group + No Receipt of Prior Season's Influenza Vaccine | 341.5 (NA to NA) | 236.1 (NA to NA) | 222.4 (129 to 369.4) | 87.5 (58.3 to 131.4) |
| Day 29 - Dose Group + No Receipt of Prior Season's Influenza Vaccine | 313 (NA to NA) | 269 (NA to NA) | 219 (129.3 to 433.7) | 104.2 (67.4 to 161.2) |
| Day 57 - Dose Group + No Receipt of Prior Season's Influenza Vaccine | 308.5 (NA to NA) | 135 (NA to NA) | 200 (118.8 to 338) | 96.2 (63.6 to 145.5) |
Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
| fold change | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Day 8 - Dose Group | 1.1 (1.0 to 1.2) | 1.6 (1.3 to 2.0) | 1.3 (1.2 to 1.5) | 1.1 (0.9 to 1.3) |
| Day 15 - Dose Group | 1.4 (1.2 to 1.7) | 1.9 (1.5 to 2.3) | 1.6 (1.4 to 1.8) | 1.0 (0.9 to 1.1) |
| Day 29 - Dose Group | 1.4 (1.2 to 1.8) | 1.8 (1.4 to 2.3) | 1.4 (1.3 to 1.6) | 1.1 (1.0 to 1.2) |
| Day 57 - Dose Group | 1.3 (1.1 to 1.6) | 1.4 (1.2 to 1.6) | 1.3 (1.2 to 1.4) | 1.2 (1.0 to 1.3) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.1 (1.0 to 1.3) | 1.6 (1.3 to 2.1) | 1.3 (1.1 to 1.5) | 1.0 (0.9 to 1.3) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.4 (1.2 to 1.7) | 1.9 (1.5 to 2.4) | 1.5 (1.4 to 1.8) | 1.0 (0.9 to 1.1) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.5 (1.2 to 1.8) | 1.8 (1.4 to 2.3) | 1.4 (1.3 to 1.6) | 1.1 (1.0 to 1.2) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.3 (1.1 to 1.6) | 1.5 (1.3 to 1.7) | 1.3 (1.1 to 1.4) | 1.2 (1.0 to 1.4) |
| Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.0 (NA to NA) | 1.3 (NA to NA) | 1.5 (1.2 to 1.9) | 1.1 (1.1 to 1.1) |
| Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.1 (NA to NA) | 1.7 (NA to NA) | 1.6 (1.1 to 2.5) | 1.0 (0.9 to 1.0) |
| Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.0 (NA to NA) | 1.9 (NA to NA) | 1.6 (1.3 to 2.0) | 1.1 (1.1 to 1.1) |
| Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.0 (NA to NA) | 1.0 (NA to NA) | 1.5 (1.2 to 1.9) | 1.0 (1.0 to 1.1) |
Titers for each participant are estimated as the geometric mean of technical replicate results, and the geometric mean is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
| Titer | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Baseline - Dose Group | 88.8 (36.1 to 197.0) | 77.3 (29.3 to 203.9) | 171.5 (115.1 to 255.5) | 160.0 (65.0 to 355.1) |
| Day 8 - Dose Group | 117.1 (45.9 to 278.6) | 117.1 (45.9 to 288.4) | 230.2 (160.0 to 331.3) | 154.5 (69.6 to 320.0) |
| Day 15 - Dose Group | 125.5 (49.2 to 278.6) | 121.3 (49.2 to 278.6) | 222.4 (149.3 to 331.3) | 165.6 (80.0 to 331.3) |
| Day 29 - Dose Group | 144.2 (52.8 to 331.3) | 117.1 (47.6 to 278.6) | 269.1 (187.0 to 394.0) | 171.5 (80.0 to 343.0) |
| Day 57 - Dose Group | 121.3 (49.2 to 278.6) | 97.0 (40.0 to 194.0) | 226.3 (154.5 to 331.3) | 154.5 (65.0 to 343.0) |
| Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine | 77.0 (29.4 to 179.6) | 71.3 (25.2 to 209.5) | 180.8 (122.7 to 266.4) | 160.0 (51.9 to 433.4) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 100.8 (37.0 to 254.0) | 113.1 (40.0 to 296.3) | 240.5 (163.3 to 354.3) | 153.2 (56.6 to 364.4) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 104.8 (40.0 to 244.4) | 113.1 (41.6 to 285.1) | 212.8 (135.9 to 333.3) | 167.1 (67.3 to 364.4) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 122.2 (43.2 to 285.1) | 104.8 (40.0 to 254.0) | 277.4 (180.8 to 417.1) | 174.5 (73.4 to 415.0) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 100.8 (37.0 to 235.2) | 91.1 (35.1 to 198.7) | 235.7 (153.6 to 354.3) | 153.2 (51.9 to 415.0) |
| Baseline - Dose Group + No Receipt of Seasonal Influenza Vaccine | 320.0 (NA to NA) | 160.0 (NA to NA) | 127.0 (40.0 to 640.0) | 160.0 (80.0 to 320.0) |
| Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 452.5 (NA to NA) | 160.0 (NA to NA) | 179.6 (80.0 to 452.5) | 160.0 (80.0 to 320.0) |
| Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 640.0 (NA to NA) | 226.3 (NA to NA) | 285.1 (160.0 to 640.0) | 160.0 (80.0 to 320.0) |
| Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 640.0 (NA to NA) | 320.0 (NA to NA) | 226.3 (113.1 to 640.0) | 160.0 (80.0 to 320.0) |
| Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 640.0 (NA to NA) | 160.0 (NA to NA) | 179.6 (80.0 to 452.5) | 160.0 (80.0 to 320.0) |
Titers for each participant are estimated as the geometric mean of technical replicate results. Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
| fold change | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Day 8 - Dose Group | 1.3 (1.1 to 1.7) | 1.5 (1.1 to 2.1) | 1.3 (1.0 to 1.7) | 1.0 (0.8 to 1.1) |
| Day 15 - Dose Group | 1.4 (1.1 to 1.9) | 1.6 (1.1 to 2.3) | 1.3 (1.0 to 1.7) | 1.0 (0.9 to 1.2) |
| Day 29 - Dose Group | 1.6 (1.3 to 2.1) | 1.5 (1.1 to 2.1) | 1.6 (1.2 to 2.0) | 1.1 (0.9 to 1.3) |
| Day 57 - Dose Group | 1.4 (1.1 to 1.6) | 1.7 (1.2 to 2.6) | 1.3 (1.1 to 1.7) | 1.0 (0.8 to 1.1) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.3 (1.1 to 1.6) | 1.6 (1.1 to 2.2) | 1.3 (1.0 to 1.8) | 1.0 (0.8 to 1.2) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.4 (1.0 to 1.9) | 1.6 (1.1 to 2.4) | 1.2 (0.9 to 1.6) | 1.0 (0.8 to 1.3) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.6 (1.2 to 2.2) | 1.5 (1.0 to 2.2) | 1.5 (1.2 to 2.0) | 1.1 (0.9 to 1.4) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 1.3 (1.1 to 1.6) | 1.8 (1.2 to 2.8) | 1.3 (1.1 to 1.6) | 1.0 (0.8 to 1.1) |
| Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.4 (NA to NA) | 1.0 (NA to NA) | 1.4 (0.7 to 2.0) | 1.0 (1.0 to 1.0) |
| Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 2.0 (NA to NA) | 1.4 (NA to NA) | 2.2 (1.0 to 5.7) | 1.0 (1.0 to 1.0) |
| Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 2.0 (NA to NA) | 2.0 (NA to NA) | 1.8 (1.0 to 4.0) | 1.0 (1.0 to 1.0) |
| Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 2.0 (NA to NA) | 1.0 (NA to NA) | 1.4 (0.7 to 4.0) | 1.0 (1.0 to 1.0) |
The geometric mean of titers is taken again across participants in each dose group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
| Titer | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Baseline - Dose Group | 32310.5 (22476.5 to 47917.6) | 21910.1 (12679.2 to 33832.9) | 43179.1 (31338.7 to 59574.7) | 27409.8 (21001.0 to 34882.0) |
| Day 8 - Dose Group | 110982.1 (56067.9 to 215643.8) | 162149.9 (88679.0 to 300949.9) | 299857.5 (198284.8 to 469239.0) | 46133.1 (32557.7 to 68073.8) |
| Day 15 - Dose Group | 300406.0 (188490.5 to 479337.5) | 351954.9 (217256.6 to 533957.5) | 967717.5 (575841.6 to 1653650.2) | 49693.2 (36201.4 to 67221.9) |
| Day 29 - Dose Group | 252954.3 (154658.1 to 400507.3) | 282368.3 (184446.3 to 401455.1) | 599513.3 (419485.4 to 850398.6) | 51515.1 (39736.0 to 67561.3) |
| Day 57 - Dose Group | 230351.2 (150357.8 to 342113.8) | 219708.4 (133947.6 to 328952.9) | 496554.5 (356138.3 to 694997.2) | 41466.5 (31949.4 to 53741.9) |
| Baseline - Dose Group + Receipt of Prior Season's Influenza Vaccine | 35718.4 (25062.8 to 52200.2) | 20762.1 (11567.3 to 34010.5) | 48734.6 (34773.3 to 68479.6) | 27638.3 (20061.6 to 36401.6) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 137098.6 (75401.8 to 253957.5) | 186797.4 (101057.6 to 349451.5) | 286800.5 (182406.6 to 478426.3) | 36667.9 (28118.5 to 49008.2) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 311658.1 (186972.3 to 517516.4) | 341659.4 (197931.1 to 541900.8) | 910946.4 (511455.4 to 1674366.8) | 42538.3 (31316.9 to 56593.7) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 278050.6 (168415.1 to 441979.2) | 270864.2 (171191.6 to 401586.7) | 600226.6 (400234.0 to 892057.4) | 45154.8 (35953.5 to 54337.9) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 255801.1 (165884.8 to 372010.5) | 210266.0 (123422.2 to 331887.5) | 483327.8 (334300.7 to 709989.0) | 35724.9 (28393.5 to 42485.4) |
| Baseline - Dose Group + No Receipt of Seasonal Influenza Vaccine | 13104.0 (NA to NA) | 35562.6 (NA to NA) | 21747.7 (13350.7 to 31668.6) | 26514.9 (18375.9 to 38258.8) |
| Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 16566.6 (NA to NA) | 45376.3 (NA to NA) | 385904.7 (189625.1 to 551293.3) | 115590.0 (82913.7 to 161143.9) |
| Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 215764.8 (NA to NA) | 459759.4 (NA to NA) | 1363110.8 (378750.2 to 4772553.5) | 92547.4 (72857.6 to 117558.3) |
| Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 107970.7 (NA to NA) | 410576.5 (NA to NA) | 595487.5 (285879.7 to 889748.5) | 87268.4 (60085.9 to 126748.0) |
| Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 89698.1 (NA to NA) | 312224.2 (NA to NA) | 578641.2 (243490.3 to 928806.1) | 75266.3 (57870.1 to 97891.8) |
Fold-rise in titers is calculated as the post-vaccination titer divided by the pre-vaccination titer. The geometric mean of fold-rises is taken again across participants in each group at each time point. Results will also be stratified by prior season's receipt of seasonal influenza vaccine within each dose group.
| fold change | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | IIV4 60 mcg |
|---|---|---|---|---|
| Day 8 - Dose Group | 3.4 (1.9 to 6.6) | 7.4 (4.2 to 12.5) | 6.9 (4.2 to 11.1) | 1.7 (1.2 to 2.6) |
| Day 15 - Dose Group | 9.3 (6.0 to 13.9) | 16.1 (10.2 to 23.8) | 22.4 (13.2 to 38.0) | 1.8 (1.2 to 2.8) |
| Day 29 - Dose Group | 7.8 (5.0 to 11.8) | 12.9 (9.2 to 18.0) | 13.9 (9.9 to 19.1) | 1.9 (1.5 to 2.6) |
| Day 57 - Dose Group | 7.1 (4.8 to 10.1) | 11.1 (7.3 to 16.4) | 11.5 (8.4 to 15.7) | 1.5 (1.1 to 2.2) |
| Day 8 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 3.8 (2.1 to 7.4) | 9.0 (5.5 to 13.9) | 5.9 (3.4 to 10.0) | 1.3 (1.0 to 1.7) |
| Day 15 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 8.7 (5.4 to 13.5) | 16.5 (9.9 to 25.2) | 18.7 (10.7 to 33.0) | 1.5 (1.1 to 2.4) |
| Day 29 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 7.8 (4.8 to 12.3) | 13.0 (8.9 to 18.6) | 12.3 (8.6 to 17.3) | 1.6 (1.4 to 2.0) |
| Day 57 - Dose Group + Receipt of Prior Season's Influenza Vaccine | 7.2 (4.6 to 10.6) | 11.5 (7.1 to 17.6) | 9.9 (7.2 to 13.9) | 1.3 (1.0 to 1.7) |
| Day 8 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 1.3 (NA to NA) | 1.3 (NA to NA) | 17.7 (14.2 to 22.7) | 4.4 (2.2 to 8.8) |
| Day 15 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 16.5 (NA to NA) | 12.9 (NA to NA) | 62.7 (28.4 to 150.7) | 3.5 (1.9 to 6.4) |
| Day 29 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 8.2 (NA to NA) | 11.5 (NA to NA) | 27.4 (21.4 to 36.6) | 3.3 (1.6 to 6.9) |
| Day 57 - Dose Group + No Receipt of Seasonal Influenza Vaccine | 6.8 (NA to NA) | 8.8 (NA to NA) | 26.6 (18.2 to 38.2) | 2.8 (1.5 to 5.3) |
Collected over Solicited AEs were collected through 13 days post-vaccination. Serious adverse events were collected through end of study participation, approximately 365 days post-vaccination. All other unsolicited AEs were collected through 28 days post-vaccination.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | 0/20 (0%) | 0/20 (0%) | 20/20 (100%) |
| Any Non-IIV4 Dose | 0/40 (0%) | 0/40 (0%) | 40/40 (100%) |
| IIV4 60 mcg | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| Event | Low Dose, 10mcg VRC H1ssF_3928 mRNA-LNP | Medium Dose 25mcg VRC H1ssF_3928 mRNA-LNP | High Dose 50mcg VRC H1ssF_3928 mRNA-LNP | Any Non-IIV4 Dose | IIV4 60 mcg |
|---|---|---|---|---|---|
| Injection site pain (Local)General disorders | 10/10 | 10/10 | 19/20 | 39/40 | 6/10 |
| Fatigue (Systemic)General disorders | 6/10 | 6/10 | 11/20 | 23/40 | 2/10 |
| Headache (Systemic)Nervous system disorders | 3/10 | 5/10 | 6/20 | 14/40 | 3/10 |
| Upper respiratory tract infectionInfections and infestations | 1/10 | 3/10 | 2/20 | 6/40 | 0/10 |
| Haemoglobin decreasedInvestigations | 3/10 | 1/10 | 3/20 | 7/40 | 0/10 |
| Myalgia (Systemic)Musculoskeletal and connective tissue disorders | 2/10 | 3/10 | 2/20 | 7/40 | 0/10 |
| Diarrhoea (Systemic)Gastrointestinal disorders | 2/10 | 1/10 | 1/20 | 4/40 | 0/10 |
| Nausea (Systemic)Gastrointestinal disorders | 1/10 | 1/10 | 3/20 | 5/40 | 0/10 |
| Chills (Systemic)General disorders | 0/10 | 1/10 | 3/20 | 4/40 | 1/10 |
| Neutrophil count decreasedInvestigations | 0/10 | 0/10 | 3/20 | 3/40 | 1/10 |
All participants
| Age, Continuous(years) | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 | Total |
|---|---|---|---|---|---|
| Mean | 33 ± 6.4 | 31.2 ± 6.8 | 36.3 ± 8 | 32.2 ± 6.1 | 33.8 ± 7.2 |
| Sex: Female, Male(Participants) | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 | Total |
|---|---|---|---|---|---|
| Female | 6 | 6 | 8 | 5 | 25 |
| Male | 4 | 4 | 12 | 5 | 25 |
| Race (NIH/OMB)(Participants) | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 1 | 1 |
| White | 10 | 9 | 19 | 7 | 45 |
| More than one race | 0 | 1 | 0 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 | 4 |
| Not Hispanic or Latino | 9 | 10 | 19 | 8 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Receipt of prior season's influenza vaccine(Participants) | Arm 1, Low Dose | Arm 2, Medium Dose | Arm 3, High Dose | Arm 4, IIV4 | Total |
|---|---|---|---|---|---|
| Count of participants | 9 | 9 | 17 | 8 | 43 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Oct 2025, 29 months.
Results were first posted in Nov 2026, 1 year 1 month after primary completion.
Of 54 non-industry phase 1 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's 29 months is above that.
Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Allergy and Infectious Diseases (NIAID) →